Programs

Clinical & Commercial Programs

AIVITA’s lead therapeutic focus is a patient-specific immunotherapy for the treatment of advanced cancers, currently being investigated in glioblastoma and melanoma. We are also developing a multi-pathogen personalized vaccine kit for the prevention of infectious diseases.

Cancer

Patient-specific dendritic cell, tumor cell immunotherapy for the treatment of glioblastoma and melanoma.

Multi-Pathogen Vaccine Kit

Patient-specific dendritic cell vaccine for the prevention of infectious diseases.

Preclinical
Phase 1
Phase 2
Phase 3
Commercialization

Tumor-initiating cell vaccine (Glioblastoma)

Tumor-initiating cell vaccine (Melanoma)

Tumor-initiating cell vaccine + checkpoint inhibitor (Melanoma)

Multi-Pathogen Vaccine Kit